hypertrophy; renin-angiotensin system; signal transduction; hypertension ALTERED VASCULAR SMOOTH MUSCLE CELL (VSMC) growth may contribute to the vascular remodeling found in small arteries in hypertension. Among many factors implicated in vascular remodeling, angiotensin II (ANG II) appears to be one of the most important. This is supported by in vivo studies (31, 39) demonstrating that angiotensin-converting enzyme inhibitors or angiotensin type 1 (AT 1 ) receptor antagonists lower blood pressure and reverse vascular remodeling in patients with hypertension and in spontaneously hypertensive rats (SHR).
giotensin type 1 (AT 1 ) receptor antagonists lower blood pressure and reverse vascular remodeling in patients with hypertension and in spontaneously hypertensive rats (SHR).
ANG II acts via at least two receptor subtypes, AT 1 and AT 2 . Signaling pathways activated by AT 1 receptors in VSMC, which mediate most of the vascular actions of ANG II, include activation of phospholipase C, phospholipase D, phospholipase A 2 , protein kinase C (PKC), NADH/NADPH oxidase, Src kinase, phosphatidylinositol-3 kinase (PI3 kinase), mitogen-activated protein (MAP) kinases [such as extracellular signalregulated kinases (ERKs), c-Jun NH 2 -terminal kinase (JNK), and p38 kinase], Janus tyrosine kinase/signal transducers of activation and transcription, and nuclear factor-B (NF-B) (34, 47) . These pathways converge and modulate the expression of certain growth factors such as platelet-derived growth factor, insulinlike growth factor-1, and basic fibroblast growth factor (45) . Several studies have reported that AT 2 receptors exert growth inhibitory and proapoptotic effects by antagonizing the action of AT 1 receptors. These actions are mediated via activation of tyrosine phosphatase(s) such as MAP kinase phosphatase (MKP)-1, anti-Src homology phosphatase (SHP)-1, and protain phosphatase 2A (PP2A) (14) and/or ceramide (34) . In contrast, other studies (31, 19, 21, 36, 37, 49) reported a growth and differentiation effect of AT 2 receptors. A proinflammatory action of AT 2 has also been reported, which is mediated via oxygen free radical-and ceramidedependent NF-B activation in VSMCs (34) .
Activation of ERK1/2-dependent pathways regulates hypertrophy, hyperplasia, and differentiation in many cell types. This intracellular signaling pathway may be altered in hypertension. Small resistance mesenteric arteries from adult SHR exhibit vascular remodeling and enhanced ANG II-induced vascular contractility (10) , which appear to be ERK1/2 dependent (45) . Furthermore, glomerular activity of ERK and JNK is chronically activated in Dahl salt-sensitive rats (11) and in ANG II-infused rats (12) . Activity of aortic ERK and JNK is also increased in Dahl salt-sensitive rats, in stroke-prone SHR, and in ANG II-infused rats (18, 51) . Furthermore, cardiac MAP kinase phosphorylation is enhanced in stroke-prone SHR (15) . Therefore, altered MAP kinase activation is evident in many tissues in various experimental models of hypertension and may be important in cardiovascular remodeling in hypertension.
Intracellular mechanisms regulating vascular ERKs in hypertension have not been fully identified. We hypothesized that Ca 2ϩ , PKC, and PI3 kinase differentially regulate ERK1/2 in SHR and normotensive control Wistar-Kyoto rats (WKY). In the present study, we therefore determined the growth effects of ANG II in VSMCs from mesenteric arteries of WKY and SHR and investigated whether intracellular Ca 2ϩ , PKC, and/or PI3 kinase, a nonreceptor tyrosine kinase, regulate vascular ERK in hypertension. Our data demonstrate that the growth-promoting actions of ANG II occur via AT 1 and AT 2 receptors in SHR VSMCs, whereas they are only mediated via AT 1 receptors in WKY VSMCs. Moreover, in SHR, these effects are mediated via ERKdependent pathways that are regulated by PI3 kinase and intracellular Ca 2ϩ but not by PKC. These novel findings define signaling pathways that may play an important role in altered ANG II-stimulated VSMC growth in hypertension. 1 and AT 2 receptors were obtained from Chemicon International (Temecula, CA) and Santa Cruz Biotechnology (Santa Cruz, CA), respectively. PD-98059, 1,2-bis(2-aminophenoxy)ethane-N,N,NЈ,NЈ-tetraacetic acid (BAPTA)-AM, bisindolylmaleimide, and LY-294002 were from Calbiochem (La Jolla, CA). Seventeen-week-old male WKY and SHR were purchased from Taconic Farms (Germantown, NY). Glass fiber filtmats were from LKB Wallac (Turku, Finland). Polyvinylidene difluoride membranes were from BoehringerMannheim (La Jolla, CA). Enhanced chemiluminescence (ECL) reagent, leupeptin, pepstatin, and aprotinin were from Roche Diagnostics (Quebec, Canada). All other reagents were from Sigma (St. Louis, MO).
MATERIALS AND METHODS

Materials
Cell cultures. VSMCs derived from mesenteric arteries were obtained by enzymatic digestion and cultured as previously described (45) . For all experiments, VSMCs were used at the same passages (between passage 3 and 6). VSMCs at 80-90% confluence were maintained in serum-free DMEM for 48 h to render cells quiescent.
[ H]thymidine (1 Ci/ml) was added for the last 4 h of incubation. To stop the reaction, the medium was withdrawn, and the cells were washed three times with cold PBS. Thereafter, cells were trypsinized (0.25 U/ml) and collected with an automatic cell harvester (LKB Wallac) onto glass fiber filtmats (LKB Wallac). The filters were dried and put into a plastic bag, to which 10 ml of scintillation cocktail was added. The radioactivity incorporated into DNA was counted in a ␤-plate counter (LKB Wallac 1205 Betaplate).
[ 1 and AT 2 receptors, respectively) were separated by 10% SDS-PAGE. Proteins were transferred to a polyvinylidene difluoride membrane, blocked in Tris-buffered saline (TBS) containing 0.1% Tween 20 (TBS-T) and 3% (wt/vol) casein, and incubated for 1 h at room temperature. The membranes were probed with antibodies against AT 1 (1/15,000 dilution) or AT 2 receptors (1/500 dilution) overnight at 4°C in TBS-T-1% casein. Thereafter, the membranes were washed in TBS-T buffer five times for 5 min and incubated in TBS-T-1% casein containing horseradish peroxidase-conjugated anti-rabbit IgG for AT 1 (1/30,000 dilution) or AT 2 receptors (1/7,000 dilution) for 1 h at room temperature. Blots were developed by ECL. Band intensity was analyzed using Image Quant software 5.0 (Molecular Dynamics).
ANG II binding assay. Receptor densities were obtained by performing competition binding experiments in subconfluent VSMCs in 24-well plates as previously described (43) . Cells were incubated for 90 min at 22°C with 0. Western blot analysis of phosphorylated ERK1/2. Cells were stimulated with ANG II in the absence and presence of BAPTA-AM (10 Ϫ5 M), bisindolylmaleimide (10 Ϫ5 M), or LY-294002 (10 Ϫ5 M) and then washed three times with cold PBS and lysed in lysis buffer, which contained 20 mM HEPES (pH 7.5), 20 mM NaCl, 1 mM orthovanadate, 1 mM sodium fluoride, 5 mM phosphoglycerol, 5 mM EDTA, 1% Triton X-100, 1 g/ml aprotinin, 0.7 g/ml pepstatin, and 1 mM phenylmethylsulfonyl fluoride. Lysed cells were centrifuged at 15,000 rpm for 20 min. Proteins (5 g) were separated by 10% SDS-PAGE. Blots were blocked in TBS-T containing 5% dry milk for 1 h at room temperature. Thereafter, blots were probed with a polyclonal phospho-specific antibody against ERK1/2 (1/2,000 dilution) in blocking buffer at 4°C overnight. Subsequently, membranes were washed in TBS-T buffer five times for 5 min. Detection was carried out using anti-rabbit horseradish peroxidase-conjugated IgG (1/5,000 dilution) in blocking buffer. Blots were developed as described above.
Statistical analysis. Results are reported as means Ϯ SE and were compared by Student's t-test or by ANOVA, fol-lowed by a post hoc Tukey-Kramer multiple comparisons test. P Ͻ 0.05 was considered significant.
RESULTS
AT 1 and AT 2 receptor expression in VSMCs.
Western blot analyses demonstrated that both AT 1 and AT 2 receptors are expressed in low-passage VSMCs from WKY and SHR (Fig. 1A) . Bands corresponded to a molecular weight of ϳ66 kDa rather than ϳ45 kDa, which suggests that the glycosylated form of the AT 1 or AT 2 receptor was detected at the same level in both WKY and SHR cells. PC12W cells, which express AT 2 but not AT 1 receptors, were used as a positive control for the AT 2 receptor. The immunoblots from these cell lysates demonstrated a band at ϳ45 kDa, the native nonglycosylated form of the AT 2 receptor. Competition binding assays with losartan and PD-123319 were carried out to measure the density of AT 1 and AT 2 receptors (Fig. 1B) (Fig. 2, top) . In contrast, ANG II, in a concentration-dependent manner, increased [ 3 H]thymidine incorporation in VSMCs from SHR but not from WKY (Fig. 2, bottom (Fig. 4) .
Activation of ERK1/2 by ANG II in VSMCs. Specific phospho-ERK1/2 antibody or ERK1/2 antibodies were used to assess ERK1/2 phosphorylation and expression, respectively. Expression of ERK1/2 was not significantly different in WKY and SHR (data not shown). ERK1/2 phosphorylation was dose dependently increased by ANG II in VSMCs from both strains. However, this response was significantly greater (twofold) in VSMCs from SHR than from WKY (Fig. 5A ). Maximum stimulation of ERK1/2 phosphorylation was observed at 10 Ϫ7 M ANG II, whereas ERK1/2 phosphorylation appeared to be reduced at high concentrations of ANG II in WKY and SHR. ANG II (10 Ϫ7 M) induced rapid ERK1/2 activation, which was maximal within 5 min of stimulation in WKY and SHR VSMCs (Fig. 5B) . (Fig. 7) . BAPTA-AM did not influence basal ERK1/2 phosphorylation. These data indicate that intracellular Ca 2ϩ may play a regulatory role in ANG II-stimulated ERK1/2 activation in WKY and SHR.
To determine whether PKC is required for ANG II-stimulated ERK1/2 phosphorylation, we used the PKC inhibitor bisindolylmaleimide (which at a dose of 10 Ϫ5 M inhibits most PKC isoforms, including PKC-) (26) . Neither the basal level nor ANG II-stimulated ERK1/2 phosphorylation were affected by this drug in VSMCs from WKY and SHR (Fig. 8A) . PKC-mediated activation of the ERK1/2 pathway is functionally intact in VSMCs, because phorbol 12-myristate 13-acetatestimulated ERK1/2 phosphorylation was abrogated by bisindolylmaleimide (Fig. 8B) .
Pretreatment of VSMCs with LY-294002, a specific PI3 kinase inhibitor, did not affect basal ERK1/2 phosphorylation. However, LY-294002 attenuated ANG IIstimulated ERK1/2 phosphorylation in VSMCs from SHR but not from WKY (Fig. 9) . These data suggest that PI3 kinase plays a role in ANG II-mediated ERK1/2-dependent pathways in SHR but not in WKY.
DISCUSSION
The major novel findings in the present study are that ANG II induces protein synthesis via AT 1 receptors in WKY VSMCs, whereas in SHR, ANG II stimulates both protein and DNA synthesis through AT 1 and AT 2 receptors in the experimental conditions used. These growth effects of ANG II are regulated by ERK1/ 2-dependent pathways, which are Ca 2ϩ sensitive and PKC independent. In SHR but not in WKY, PI3 kinase plays an important role in ANG II-induced VSMC growth. These data suggest that mechanisms stimulating growth in VSMCs from SHR involve a PI3 kinasedependent ERK1/2-regulated pathway and are different from those present in WKY VSMCs.
Both AT 1 and AT 2 receptor subtypes were expressed in VSMCs from WKY and SHR. AT 1 and AT 2 receptor subtypes are glycoproteins with at least three asparagine motif sites of glycosylation (20, 40) . Conflicting data concerning the size of AT 1 and AT 2 receptor subtypes have been reported. The range of molecular mass values of these receptors varies between 41 and 140 kDa, depending on the level of glycosylation and phosphorylation. The lower molecular mass corresponds to the nonglycosylated form of the receptors, which are located mainly in the endoplasmic reticulum and Golgi apparatus. Moreover, the ligand-binding properties of AT 1 and AT 2 receptors to ANG II are not affected by the level of glycosylation (20, 40) .
Competition binding assays showed the presence but did not allow quantification of the density of AT 2 receptors in VSMCs. It is well know that the expression of AT 2 receptors is very low in adult VSMCs. The technique was not sensitive enough to precisely quantify their very low density (Ͻ30 fmol/mg of proteins) (43) . With the use of a specific AT 2 radioligand ([ 125 I]-labeled CGP-42112A), Kambayashi et al. (16) found that aortic SMCs expressed ϳ15 fmol/mg of AT 2 receptor binding sites. This amount of receptor was detect- 
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able by Western blot (34) . We performed Western blot analysis, which revealed the presence of AT 2 receptors in mesenteric VSMCs from WKY and SHR, using the same antibody as Ruiz-Ortega et al. (34) . Thus mesenteric VSMCs do appear to express low densities of AT 2 receptors even if they cannot be quantified by radioligand assay. Although the density of AT 2 receptors was much lower than that of AT 1 receptors, an effect of AT 2 receptors on growth of VSMC from SHR was observed, as demonstrated by the growth-inhibitory effect of the AT 2 receptor-selective antagonist. AT 2 receptors contribute to VSMC growth in SHR by unknown mechanisms. These findings are supported by results from Ruiz-Ortega et al. (34) , who demonstrated that the AT 2 receptor mediates ANG II-induced NF-B activation in aortic SMCs.
The AT 1 receptor has been linked to vascular remodeling because of its implication in SMC hypertrophy and/or hyperplasia, extracellular matrix deposition, and inflammatory responses. In contrast, the physiological function of AT 2 receptors has not been clearly defined, although several studies suggest that they have a proapoptotic effect on VSMCs from normal rats. Other studies (34, 49) suggest that AT 2 receptors play a role in differentiation and inflammation. The AT 2 receptor is expressed in adult tissues such as the brain, heart, aorta, mesenteric arteries, and renal and skeletal muscle vasculature (3, 28, 31, 41) . In this study, ANG II induced hypertrophy in VSMCs from WKY and hypertrophy/hyperplasia in VSMCs in SHR. Hypertrophy and hyperplasia induced by ANG II seem to be mediated via AT 1 and AT 2 receptors in VSMCs from SHR. To our knowledge, these data demonstrate for the first time the role of the AT 2 receptor in VSMC growth from SHR. AT 2 receptor-mediated cell growth has been demonstrated in other cells such as A10 smooth muscle cell (37) and endothelial and cardiac fibroblasts after myocardial infarction (19) . Previous in vivo studies have revealed controversial results concerning the role of the AT 2 receptor on VSMC growth in different rat models of experimental hypertension. Levy et al. (21) and Sabri et al. (36) reported that the AT 2 receptor mediated aortic and coronary artery hypertrophy and differentiation, whereas Li et al. (22) found that AT 1 receptors mediate vascular hypertrophy in different vascular beds in chronic ANG IIinfused Wistar rats. However, Cao et al. (3) demonstrated that both AT 1 and AT 2 receptors mediated mesenteric vascular hypertrophy and VSMC proliferation in ANG II-infused rats. AT 2 receptors have also been shown to induce aortic SMC hypertrophy in SHR (31) . These discrepancies may be related to different ages and strains of rats, different models of hypertension, or different experimental conditions. The exact role of AT 2 receptors in the regulation of VSMC growth and differentiation in hypertension awaits further clarification.
ANG II induces phosphorylation on tyrosine residues of many proteins, including ERK1/2. These kinases are implicated in cell growth. Results from the present study demonstrate that inhibition of MEK, and subsequently ERK1/2 inhibition, attenuated protein and DNA synthesis induced by ANG II in VSMCs from WKY and SHR, respectively. Kinetic studies reveal that in SHR VSMCs, ERK1/2 phosphorylation was enhanced and sustained compared with WKY VSMCs. These responses were independent of ERK1/2 expression because expression of ERK1/2 was the same in WKY and SHR-derived cells. ERK1/2 activation induced by ANG II or insulin was higher in aortic SMCs derived from SHR than in those derived from WKY (2, 48) . Similar results have been observed in VSMCs derived from hypertensive patients (46) . Mii et al. (27) , who studied the kinetics of ERK1/2 activation, demonstrated that the proliferative potency of an agonist depends on the duration of ERK1/2 activation. The abnormal ERK1/2 activity induced by ANG II in SHR cells may underlie the enhanced proliferative effect of ANG II in hypertension. In addition, this could also be a consequence of activity of phosphatases such as MKP-1, implicated in ERK1/2 dephosphorylation.
ANG II-stimulated ERK1/2 phosphorylation was mediated via AT 1 receptors in VSMCs from SHR and WKY. AT 2 receptors have been suggested to counteract the AT 1 receptor-mediated tyrosine kinase activation by inducing phosphotyrosine phosphatase activation and to subsequently inhibit cell proliferation by modulating ERK1/2 activation (14) . Although VSMCs expressed AT 2 receptors, ANG II-stimulated ERK1/2 phosphorylation was not exaggerated in the presence of PD-123319, which suggests that the AT 2 receptor is not coupled to ERK1/2-dependent signaling pathways.
To clarify the intracellular mechanisms underlying augmented ANG II-stimulated ERK1/2 phosphorylation in SHR cells, we investigated the modulatory role of three different pathways that have been shown to control ERK1/2 activation: intracellular Ca 2ϩ , PKC, and PI3 kinase. ANG II increases intracellular Ca 2ϩ , leading to VSMC contraction, which may be dependent on ERK1/2 activation (45). Ca 2ϩ modulates various upstream kinases of the ERK1/2 pathway such as Ca 2ϩ /calmodulin-dependent protein kinase II (1) and proline-rich tyrosine kinase 2 (6, 35). Eguchi et al. (9) showed a Ca 2ϩ -dependent transactivation of the epidermal growth factor (EGF) receptor, leading to ERK1/2 activation induced by ANG II. Our data demonstrated the same dependency of Ca 2ϩ -mediated ERK1/2 activation by ANG II in cells derived from WKY and SHR. In contrast, Lucchesi et al. (24) reported a greater dependency on Ca 2ϩ in ANG II-stimulated ERK1/2 in aortic SMCs derived from SHR compared with those derived from WKY. This difference in the control of ANG II signaling pathways confirms that different responses may be found in VSMCs from different vascular beds (42) .
The expression pattern of PKC isoforms differs between different vascular beds. Of the 12 known members of the PKC family, rat mesenteric VSMCs express classic (␣ and ␥), novel (␦ and ⑀), and atypical () isoforms (29) . PKC plays an important role in ANG II signaling pathways and has been implicated in ANG II-induced VSMC contraction (30) and growth (13) . In our study, PKC inhibition did not alter ANG IIinduced actions, suggesting that ERK1/2-mediated growth effects in mesenteric VSMCs in WKY or SHR are not dependent on PKC, in agreement with previous results (8, 13) . However, some studies (25, 48, 52) have demonstrated that PKC downregulation or PKC inhibition decreased ERK1/2 phosphorylation. Some isoforms, such as PKC-⑀ and -, have been implicated in ERK1/2 activation induced by ANG II in rat aortic SMCs (25) and human vein SMCs (23) . Thus it seems likely that PKC-dependent ERK1/2 activation is cell type specific.
Intracellular signaling pathways mediated via PI3 kinases regulate several cell functions such as mitogenesis, differentiation, and cell motility and survival (44) . ANG II phosphorylates and activates PI3 kinase in VSMCs (38) . The mechanism whereby ANG II induced PI3 kinase activation is unclear, but EGF receptor transactivation may be important, because ANG II phosphorylates and activates EGF receptors (9) . The EGF receptor is linked to the PI3 kinase pathway. It is also possible that ANG II stimulates PI3 kinase directly, because the ␤␥-complex of heterotrimeric G proteins activates PI3 kinases (17) . There is emerging evidence that activation of VSMC ERK1/2 by some agonists is mediated by PI3 kinases in SMCs (4, 5, 32, 33) . Because PI3 kinase inhibition affected only ANG II-stimulated ERK1/2 activation in SHR cells, this provides evidence that PI3 kinase-dependent ERK1/2-activated pathways may play a role in SHR but not in WKY. This is supported by another study (50) demonstrating that PI3 kinase activity is increased by ANG II, and this has a modulatory effect on neurons from SHR but not from WKY. ANG II-induced ERK1/2 has also been shown to be independent of PI3 kinase in VSMCs from the Sprague-Dawley rat (7).
In conclusion, the present study demonstrates novel differential growth effects and signaling pathways of ANG II in VSMCs from WKY and SHR. In SHR VSMCs, ANG II induces proliferation via AT 1 and AT 2 receptors. In contrast, in WKY rats, ANG II induces VSMC hypertrophy exclusively via AT 1 receptors. The signal transduction pathways that mediate AT 1 receptor-induced proliferation in SHR VSMCs are associated with enhanced and sustained ERK1/2 activation regulated by PI3 kinase-mediated Ca 2ϩ -sensitive pathways independent of PKC. The mechanisms through which AT 2 receptors contribute to cell growth in SHR VSMCs require further investigation. Our observations may explain, in part, processes whereby ANG II induces its pathological growth effects in VSMCs from SHR, contributing thus to blood pressure elevation in this genetic model of hypertension. 
